Table II.
Intensity of immunostaining for PRDXs in normal endometrial tissue from cancer and endometrial cancer samples.
| Staining intensity, n (%) | ||||||
|---|---|---|---|---|---|---|
| PRDX isoform | Sample type | No. of samples | + | ++ | +++ | P-value |
| 1 | Normal | 24 | 5 (20.8) | 7 (29.2) | 12 (50.0) | NS |
| Cancer | 42 | 17 (40.5) | 19 (45.2) | 6 (14.3) | ||
| 3 | Normal | 19 | 3 (15.8) | 10 (52.6) | 6 (31.6) | 0.0001a |
| Cancer | 42 | 6 (14.3) | 11 (26.2) | 25 (59.5) | ||
| 5 | Normal | 34 | 8 (23.5) | 7 (20.6) | 19 (55.9) | 0.0023a |
| Cancer | 42 | 3 (7.1) | 7 (16.7) | 32 (76.2) | ||
| 6 | Normal | 25 | 5 (20.0) | 16 (64.0) | 4 (16.0) | NS |
| Cancer | 42 | 12 (28.6) | 22 (52.4) | 8 (19.0) | ||
a
Statistically significant (P<0.05). The total number of normal endometrial samples differs as samples that were not stained were excluded. PRDX, peroxiredoxin; +, weak staining; ++, moderate staining; +++, strong staining; NS, no significance.